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Abstract
Autism spectrum disorder (ASD) risk is influenced by common polygenic and de novo variation. 
We aimed to clarify the influence of polygenic risk for ASDs and to identify subgroups of ASD 
cases, including those with strong acting de novo variants, in which polygenic risk is relevant. 
Using a novel approach called the polygenic transmission disequilibrium test, and data from 6,454 
families with a child with ASD, we show that polygenic risk for ASDs, schizophrenia, and greater 
educational attainment is over transmitted to children with ASDs. These findings hold independent 
of proband IQ. We find that polygenic variation contributes additively to risk in ASD cases who 
carry a strong acting de novo variant. Lastly, we show that elements of polygenic risk are 
independent and differ in their relationship with phenotype. These results confirm that ASDs’ 
genetic influences are additive and suggest they create risk through at least partially distinct 
etiologic pathways.
Introduction
Risk for autism spectrum disorders (ASDs) is strongly genetically influenced, and reflects 
several types of genetic variation1–7. Common polygenic variation, distributed across the 
genome, accounts for at least 20% of ASD liability2, 5, 8, 9. De novo single nucleotide and 
copy number variants can strongly affect the individuals who carry them1, 3, 4, but account 
for less liability at a population level (< 10%)2. Over the last several years, the common 
polygenic and de novo influences on ASD risk have been increasingly well characterized, 
particularly in terms of the distribution of their phenotypic effects. Most consistently, ASD-
associated de novo variants have been strongly linked to intellectual disability, as well as 
other indicators of global neurodevelopmental impact (e.g., seizures; motor delay)1, 10. 
Indeed ASD-associated de novo mutations that yield protein truncations are far more 
commonly observed in global developmental delay than in autism itself11.
Recent studies have suggested that the common polygenic component of ASDs has a 
different, perhaps surprising, relationship with cognition. Polygenic risk for ASDs has been 
positively associated with intelligence and educational attainment in several reports6, 12–14. 
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In other words, in the general population, greater common variant risk for ASDs is 
associated with higher IQ. These findings are difficult to interpret – on average, IQ in ASD 
is at least a standard deviation below the population mean1, 15. Further, ASDs share 
approximately 25% of their common variant influences with schizophrenia, and 
schizophrenia itself shows a negative genetic correlation with IQ6, 14. While genetic 
correlation analyses are not expected to be transitive, this particularly complex network of 
common variant associations has led to concerns about confounding resulting from 
ascertainment and case heterogeneity16.
Here we attempt to clarify the influence of common variant risk for ASDs, and to better 
understand the subgroups of ASD individuals for whom polygenic variation is risk 
contributing. We thus sought to employ a robust family-based design that would be immune 
to many of the potential confounders that can arise in attempting to construct a well-matched 
case-control comparison. To advance this analysis we extended the transmission 
disequilibrium approach to encompass polygenic risk scores; we call the resulting 
methodology the polygenic transmission disequilibrium test (pTDT). Using pTDT we then 
show that common polygenic predictors of (i) ASDs, (ii) schizophrenia, and (iii) years of 
educational attainment are unambiguously associated with ASD risk, independent of the 
presence of intellectual disability in cases. We find that common polygenic variation still 
contributes to ASD risk in cases that carry a very strong acting de novo event. Lastly, we 
find that the three aforementioned polygenic risk factors have independent and distinct 
effects on phenotypic heterogeneity in ASD, suggesting that components of common 
polygenic variation also behave additively and operate through at least partially distinct 
etiologic pathways.
Children are expected to inherit half of their parents’ risk alleles for a trait. This expectation 
forms the basis of several commonly used tests of genetic association. The classic 
transmission disequilibrium test, for example, examines the frequency with which single 
genetic variants are transmitted from parents to their children17. Variants transmitted 
significantly more than half of the time from unaffected parents to children affected with 
some trait or condition are nominated for association with that trait – only the ascertainment 
on a trait in the offspring and the association of the allele with the trait introduces deviation 
from the 50-50 chance of inheriting either allele from a heterozygous parent. Transmission 
disequilibrium tests have several convenient properties. First, they are immune to 
confounding by ancestry. They are also less vulnerable to bias from other potential 
differences between cases and controls, such as socioeconomic background or other factors 
commonly related to case ascertainment since the ‘controls’ are, in effect, the perfectly 
matched untransmitted chromosomes.
In this study, we extend the transmission disequilibrium test to polygenic risk scores and 
introduce the polygenic transmission disequilibrium approach. A polygenic risk score (PRS) 
provides a quantitative measure of an individual’s genome-wide common variant 
predisposition (or “risk”) for a trait (Online Methods: Polygenic Risk Scoring). PRS are 
normally distributed in the population, which means that some degree of common variant 
risk for complex traits like ASDs is present in all of us. Since a child has a 50% chance of 
inheriting either allele from a heterozygous parent, it is algebraically defined that the 
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expected value of a child’s PRS for any trait will be equal to the average of their parents’ 
PRS (mid-parent PRS). This expectation is broken when offspring are specifically 
ascertained for a phenotypic deviation from their parents (Supplementary Figure 1), for 
example children who are much taller than their parents or children affected with ASD when 
their parents are not. In the example of ASD, we would then expect the affected child to 
have received more of their parents ASD risk alleles than expected by chance9. From that, 
the average offspring PRS for an ASD-associated trait would be greater than the average 
mid-parent PRS. By comparing ASD individuals’ PRS for various traits against those of 
their unaffected parents, one can unambiguously associate specific types of common variant 
risk (e.g., polygenic risk for schizophrenia, educational attainment) with ASDs, and query 
the subsets of cases in which those risk factors are most relevant.
We used two independent ASD family cohorts to examine transmission of polygenic risk 
(Online Methods: Sample Description; Supplementary Table 1). The Simons Simplex 
Collection (SSC) is a resource of more than 2,500 families with a single child diagnosed 
with ASD18. No other family members to the level of first cousins had an ASD diagnosis. 
Genotype data were available for the parents, the affected child, and an unaffected sibling 
for 2,091 SSC families (quad families). An additional 493 SSC families had available data 
for the parents and the affected child alone (trio families). Most genotyped individuals in 
SSC were exome sequenced in previous studies (89.0%)4. Our independent Psychiatric 
Genomics Consortium ASD (PGC ASD) sample consisted of 3,870 genotyped parent-child 
trios from the Psychiatric Genomics Consortium Autism Group (Supplementary Table 2). 
The PGC ASD cohort described here does not include individuals from the SSC, and the 
data set does not include exome sequence information.
We calculated common polygenic risk for ASDs, educational attainment (EA) and 
schizophrenia (SCZ) for all genotyped family members in the SSC and PGC ASD datasets 
using a standard approach (Online Methods: Polygenic Risk Scoring)19. In addition to 
polygenic risk for ASD itself, we chose to examine polygenic risk for EA and SCZ as those 
phenotypes have been most strongly linked to ASD in genome-wide genetic correlation 
studies6, 14, 20. To build the polygenic predictors, we used summary statistics from the 
largest independent genome-wide association studies of each phenotype (Supplementary 
Table 3). The discovery GWAS (including ASD) did not include any SSC or PGC ASD 
individuals. Using the calculated polygenic risk scores, we first examined properties of their 
distribution in the parents. Analyzing the SSC and PGC ASD cohorts separately, we did not 
observe any consistent correlations between the parents’ PRS, for any pair of PRS, and 
based on that no PRS-based evidence of assortative mating (Supplementary Note 1, 
Supplementary Tables 4, 5). We also found no evidence that the mothers and fathers of 
children with ASD differ with regard to the common variant risk that they carry 
(Supplementary Note 2, Supplementary Table 6). Lastly, there was no evidence that mid-
parent polygenic risk differs by proband sex (Supplementary Note 3, Supplementary Table 
7).
The pTDT is a t-test asking whether the mean of the offspring PRS distribution is consistent 
with its parentally-derived expected value (Online Methods: pTDT). In brief, for each trio, 
one averages the parent PRS for a given trait to generate the mid-parent value, and then 
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subtracts that value from the proband’s PRS for the same trait. To standardize and improve 
interpretability, we divide the resulting difference by the standard deviation of the (observed) 
mid-parent distribution. This yields the estimated pTDT deviation, and the pTDT then tests 
whether the average pTDT deviation across all offspring differs from zero. A mean pTDT 
deviation of 0.1 for the ASD PRS, for example, would indicate that the offspring’s ASD 
PRS is on average 0.1 standard deviations higher than that of their parents.
Results
Polygenic Transmission Disequilibrium
For each of ASD, SCZ, and EA, we calculated the average pTDT deviation for each affected 
child in the SSC and PGC ASD, as well as for each unaffected sibling in the SSC. The 
primary pTDT results are shown in Figure 1a. In both the SSC and PGC ASD samples, 
polygenic risk for each of ASD, EA, and SCZ was significantly over transmitted to affected 
children (P < 1E-06 for all comparisons), but not to SSC unaffected siblings (P > 0.05 for all 
comparisons; Figure 1a). This means that common polygenic risk defined in GWAS studies 
of ASD, SCZ, and greater EA are each unambiguously associated with autism spectrum 
disorders. The results did not change when the SSC and PGC ASD samples were restricted 
to families of European ancestry (Supplementary Note 4; Supplementary Table 8, 
Supplementary Figures 2, 3). We repeated the analysis in the SSC and PGC ASD using a 
PRS for body mass index (BMI) – a polygenic risk category unassociated with ASD6 – as a 
negative control (Online Methods: Polygenic Risk Scoring). As expected, we found that 
neither ASD probands nor unaffected siblings over inherited BMI PRS (P > 0.05 for all 
comparisons) (Supplementary Table 9).
The degree of polygenic over transmission did not differ between SSC and PGC ASD 
probands for any comparison (P > 0.05 for all comparisons; Supplementary Table 10), so we 
combined the samples to improve the power of subsequent subgroup analyses. Using the 
combined data, each PRS is over transmitted to both male and female probands (P < 0.05 for 
all comparisons; Figure 1b). In Figure 1c, we also see that each of the three PRS are 
significantly, and equally, over transmitted to ASD cases with measured IQs in the 
intellectual disability range (IQ < 70, (Online Methods: pTDT; Supplementary Tables 11, 
12) when compared with those without intellectual disability. Most probands in the 
intellectual disability group do not have an observed genetic event that might explain their 
low IQ, for example a de novo mutation from an ASD-associated class, and repeating the 
analysis in the low IQ SSC probands with de novo carriers removed did not change the 
observed associations (Online Methods: De novo variant analyses; Supplementary Table 
13).
Common and rare variant additivity
In order to best interrogate additivity between common polygenic and rare, strong acting 
variation, we defined a group of de novo mutations of large effect (Supplementary Table 14). 
We previously identified a subclass of de novo protein truncating variants (contributing 
PTVs) responsible for almost all of the PTV association to ASDs21 (Online Methods: De 
novo variant analyses). As de novo copy number variants (CNVs) that delete a gene should 
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have the same, if not greater, molecular impact as a PTV in that gene, we were motivated to 
investigate whether we could similarly refine ASDs’ association with de novo deletions 
(Online Methods: De novo variant analyses). In the SSC, we found that ASDs were 
strongly associated with de novo deletions from two categories: a) deletions that include a 
constrained gene predicted to be intolerant of heterozygous loss of function variation 
(probability of loss of function intolerance (pLI) ≥ 0.9)22, and b) uncommon, large (≥ 500 
kilobase) deletions that do not contain a constrained gene (from here: contributing CNV 
deletions; Supplementary Figure 4, Supplementary Figure 5).
Together, these refined classes of de novo PTVs and deletions form a category of strong 
acting de novo variants (from here: contributing de novo variants (CDNVs); odds ratio (OR) 
= 3.91, P = 6.56E-20; case rate = 9.4%; control rate = 2.6%). Consistent with a hallmark of 
ASD-associated de novo variation, Figure 2a shows that the rate of CDNVs in SSC varies 
substantially based on the probands’ counts of co-occurring adverse neurodevelopmental 
outcomes, in this case the count of: delayed walking, a history of seizures, or intellectual 
disability (Online Methods: De novo variant analyses; Supplementary Table 15). ASD 
probands without any of those comorbid traits were more than 3 times (OR = 3.15; P = 
3.88E-10) as likely to carry a CDNV than their unaffected siblings; ASD probands with all 
three of these comorbid traits were approximately 15 times as likely to carry a CDNV than 
their unaffected siblings (OR = 15.05; P = 9.08E-10). Because de novo events observed in 
cases and controls differ with regard to their average severity23, their effect size cannot be 
directly estimated using the case-control carrier ratio. Using the male:female carrier 
approach described by De Rubeis et al.3, we estimate that, on average, the CDNVs defined 
here confer an approximate 20-fold increase in risk for an ASD diagnosis (Online Methods: 
De novo variant analyses). Their effect size, however, likely varies as the male:female ratio 
of the carriers declines with increasing neurodevelopmental comorbidities (Supplementary 
Table 16). In other words, the CDNVs seen in the ASD individuals with multiple comorbid 
neurodevelopmental traits are likely, on average, more deleterious than those seen in 
probands with ASD alone.
Shown in Figure 2b, we used pTDT to determine whether polygenic risk for ASD, SCZ, and 
EA was also over transmitted to CDNV carriers (Online Methods: De novo variant 
analyses). ASD cases with a CDNV (n = 221 cases) indeed carried more polygenic risk for 
ASD and SCZ than expected based on parent background (P < 0.05 for both comparisons). 
There was no evidence of over transmission of EA PRS (P = 0.80), though a larger number 
of ASD cases with a CDNV will be required to differentiate a true null in this instance from 
an issue of power. Over transmission of the ASD and SCZ PRS provides clear evidence for 
additivity between common and rare variation in creating risk for ASDs. We did not see a 
difference in polygenic over transmission between probands with zero versus one or more 
co-occurring neurodevelopmental outcomes (P > 0.05 for all comparisons; Supplementary 
Table 17), further supporting the consistent influence of polygenic risk factors.
Additivity among common polygenic risk factors
In the context of three orthogonal risk distributions, each of which is associated with ASDs, 
one does not have to maintain an extreme position on any single distribution to carry a 
Weiner et al. Page 6
Nat Genet. Author manuscript; available in PMC 2017 November 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cumulatively uncommon amount of ASD risk (Figure 3a). For example, being in the top 
20% of three uncorrelated ASD risk distributions would result in a cumulative amount of 
risk seen in less than 1% of people in the population (0.23=0.008).
Common polygenic risk for ASDs, SCZ, and EA is partially correlated6. As shown in Figure 
3b, however, we observed little evidence of correlation between the ASD, SCZ, and EA PRS 
in terms of either a) correlation at the mid-parent level, above the diagonal or b) correlation 
in the degree to which the scores were transmitted to the probands (pTDT deviation), below 
the diagonal. The lack of strong associations is likely a function of both ascertainment 
effects and attenuation due to limited predictive ability of the PRS.
Given limited association between the three PRS, we were able to examine additivity among 
largely distinct common polygenic risk factors. First, we saw significant evidence that each 
of the three PRS were independently over transmitted (P < 2E-04 in all SSC + PGC ASD 
comparisons; Online Methods: Genetic heterogeneity; Supplementary Table 18). This 
means that ASD risk is influenced by elements unique to each of the scores, as well as by 
elements that are shared among them. Independent influences are further suggested by the 
scores’ relationship with proband IQ (Supplementary Table 19). In Figure 3c, we show the 
association between each PRS and full scale proband IQ in European ancestry SSC 
probands, controlling for sex, presence of CDNVs, the other two PRS, and the first 10 
principal components of ancestry (Online Methods: Genetic heterogeneity). The EA and 
SCZ PRS are associated with proband IQ in opposite directions, consistent with the patterns 
observed in the general population (Supplementary Table 19)14.
In addition to statistical evidence of unique contributions, the phenotypic associations 
suggest that the three PRS are influencing ASD risk through at least partially different 
processes. Polygenic risk for SCZ influences ASD liability in a manner that negatively 
influences cognition. Polygenic risk for EA influences ASD liability in a manner that 
positively influences cognition. These findings reinforce the idea that ASD heterogeneity is 
shaped not only by rare variants of strong effect, but also by diverse common variant risk 
factors acting through multiple biological pathways.
Discussion
Despite longstanding evidence for common polygenic influences on ASD risk, many have 
questioned those associations, particularly the recently published – and counterintuitive – 
findings from genetic correlation analysis. Using pTDT, we have shown an unambiguous 
association between ASD risk and the common polygenic influences on: ASDs themselves, 
schizophrenia, and greater educational attainment. These effects were evident in affected 
males and affected females, as well as ASD individuals with and without intellectual 
disability. Because of the strong correlation between the polygenic influences on educational 
attainment and intelligence14, this finding means that, on average, individuals with ASD and 
intellectual disability have inherited more IQ increasing alleles than their typically 
developing siblings. That association, which replicated in independent ASD cohorts and 
held in probands without an ASD-associated de novo event, will require further study. With 
regard to proband phenotype, the finding furthers existing questions of whether an IQ 
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measured below 70 in someone with an ASD might be different in some ways from an IQ 
measured below 70 in someone without. With regard to better understanding the 
mechanisms through which genetic risk is conferred, we need to examine how and when 
certain amounts of risk are beneficial (e.g., a strong interest in the arts or sciences that 
increases one’s educational attainment), and how and when they are deleterious (e.g., an 
overwhelming interest in a topic that disrupts healthy and necessary activities). Genetic risk 
and phenotypic traits relevant to neuropsychiatric disease exist on continua24, for which 
effective research and treatment paradigms will likely need to account.
These findings also highlight important differences between the common and rare variant 
contributors to ASD risk. Strong acting, de novo variant risk for ASDs impacts a limited 
subset of cases. The phenotypic preferences of those types of variants are now well 
established; they are associated with intellectual disability, seizures, and global 
neurodevelopmental impact1. Common variant risk factors, on the other hand, appear more 
pervasively influential among ASD cases. Common variant risk appears similarly relevant to 
ASD individuals with high and low IQ, and with and without a large acting de novo 
mutation. The common polygenic influences also appear comparatively neurologically 
gentle. They are, in many cases, in fact associated with better educational and cognitive 
outcomes in the population. These differences strongly suggest that de novo and common 
polygenic variation may confer risk for ASD in different ways. Particularly as common 
polygenic risk is the more consistent contributor to ASD liability across cases, it will be 
critically important to take common variation into account in creating animal or stem cell 
models of ASD.
The pTDT approach can be broadly used to interrogate and clarify polygenic relationships. 
As a family-based approach, pTDT is immune to ancestral stratification and is less likely to 
be confounded by other influences on case ascertainment, for example socioeconomic status. 
While pTDT achieves optimal power comparing offspring with parents, it can be easily 
adapted to compare probands and unaffected siblings, and its predictive ability will improve 
through additional methodological development and larger discovery sample sizes. A 
command line tool to assist with pTDT analysis is publically available at: https://github.com/
ypaialex/ptdt.
Online Methods
Sample Description
The analytic cohorts are presented in Supplementary Table 1. The research specific to this 
study was approved by the Partners Healthcare Institutional Review Board. The Simons 
Simplex Collection (SSC) is a resource of more than 2,500 families with a child diagnosed 
with an autism spectrum disorder (ASD)18. Informed consent and assent was provided for 
all subjects. Each member of the family was genotyped on one of the following platforms: 
Illumina Omni2.5, Illumina 1Mv3 or Illumina 1Mv11. We analyzed 2,091 SSC quads, 
defined as families with both parents, the proband, and a designated unaffected sibling 
genotyped, and 493 SSC trios, defined as families with both parents and the proband 
genotyped. Most SSC families were also whole exome sequenced to detect rare coding 
Weiner et al. Page 8
Nat Genet. Author manuscript; available in PMC 2017 November 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
variation (82.7% of quads, an additional 8.0% of quads without sibling sequencing; 91.1% 
of trios).
The Psychiatric Genomics Consortium Autism Group (PGC ASD) sample consisted of 
parent-proband trios from the Psychiatric Genomics Consortium Autism Group 
(Supplementary Table 2). Our PGC ASD analytic sample excluded the SSC families present 
in the PGC ASD genome-wide association study (GWAS)20. The PGC ASD sample 
described here is accordingly independent from the SSC sample and included 3,870 parent-
proband trios. In brief, the PGC ASD data included ASD trio cohorts from: Autism Center 
of Excellence UCLA (n = 215), Autism Genome Project (n = 2,254), Montreal/Boston 
Collection (n = 138), Johns Hopkins University (n = 764), and the Children’s Hospital of 
Philadelphia (n = 499)20. All genotype data (SSC and PGC ASD) were imputed using the 
1000 Genomes reference panel and Ricopili pipeline, which are publicly available and have 
been reported on extensively19, 25, 26.
Though trio approaches are broadly immune to confounding through ancestry, we isolated 
European-only subsets of both the SSC and PGC ASD samples to a) ensure that our primary 
results did not change in an ancestrally homogeneous subset of the data and b) conduct 
comparisons across probands or across parents, which might be sensitive to ancestry (as 
opposed to comparisons between probands and parents in a trio). In the SSC, we first 
selected probands with parent-reported white non-Hispanic ancestry (n = 1,912). We merged 
the genotype data from those individuals with the Hapmap III dataset27 and generated 
principal components of ancestry using GCTA28. Through visual inspection (Supplementary 
Figure 6), we defined an ancestrally European SSC subcohort, leaving 1,851 probands (and, 
by extension, 1,851 families). We calculated principal components of ancestry distinctly 
within the derived SSC European ancestry subcohort and used these as covariates in the non-
trio analysis (e.g., genotype to phenotype analyses among probands).
Self-reported ancestry was not available for the PGC ASD samples. To conservatively 
isolate a European ancestry PGC ASD subcohort, we identified those families in which both 
parents were of European ancestry. To do so, we merged the PGC ASD parent data with 
Hapmap III and similarly generated principal components of ancestry using GCTA. By 
visual inspection, we identified European ancestry individuals, leaving 6,742 of the original 
7,740 PGC ASD parents (Supplementary Figure 7). Both parents were of European ancestry 
in 3,209 families, and those families comprised the European ancestry PGC ASD subcohort. 
We again calculated principal components of ancestry within the derived PGC ASD 
European ancestry subcohort for use as analytic covariates in non-trio analyses.
Polygenic Risk Scoring
A polygenic risk score (PRS) provides a quantitative estimate of an individual’s genetic 
predisposition (“risk”) for a given phenotype based on common variant genotype data and 
independent GWAS results for the target phenotype (e.g., schizophrenia or educational 
attainment)29. The score provides a relative, not absolute, measure of risk. For example, 
individual A (PRSschizophrenia = 8) is at higher estimated genetic risk for schizophrenia than 
individual B (PRSschizophrenia = 6), but a PRS of 8 or 6 is not independently interpretable.
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We calculated polygenic risk for ASD, educational attainment (EA), schizophrenia (SCZ) 
and body mass index (BMI) for all individuals with available genotype data in the SSC and 
PGC ASD datasets. To do so, we used summary statistics from the largest available, 
independent GWAS of each phenotype (Supplementary Table 3). None of the subjects in the 
SSC or PGC ASD cohort were included in any of the four GWAS discovery samples. We 
selected SCZ and EA because of their robust, well-replicated associations with ASD 
risk6, 14, 20. We selected BMI as a negative control due to its lack of association with ASD 
risk6. We used ASD summary statistics from a GWAS of a Danish population-based sample 
of 7,783 cases and 11,359 controls from the first 10 genotyping waves of the iPSYCH-Broad 
Autism project24. The SCZ summary statistics were from the 2014 GWAS of 36,989 cases 
and 113,075 controls from the Psychiatric Genomics Consortium19. The EA summary 
statistics were from a population-based GWAS of years of schooling (n = 328,917, discovery 
and replication meta-analysis, excluding 23andMe)12. The BMI summary statistics were 
from a population-based GWAS of body mass index (n = 322,154, European ancestry meta-
analysis)30.
To construct the polygenic risk scores, we first gathered the summary statistics from the 
GWAS described above. The summary statistics included effect sizes and p-values for each 
single nucleotide polymorphism (SNP) in the imputed GWAS analysis, typically 
approximately 10 million markers. We then employed the widely used Ricopili pipeline to 
generate the PRS19. In brief, Ricopili first removes SNPs within 500 kilobases of and 
correlated (r2 ≥ 0.1) with a more significantly associated SNP in the GWAS. We used the 
1000 Genomes Reference panel to estimate SNP correlations25. This process typically 
reduces the SNP list to fewer than 300,000 markers. For complex, polygenic traits, only a 
small fraction of those SNPs remaining pass the genome-wide significance threshold of P = 
5.00E-08; the majority of the signal resides in SNPs that do not pass the significance 
threshold and cannot be specifically identified 6, 12, 19, 28. In order to maximally capture 
common, polygenic influence, we therefore relaxed the p-value threshold for SNPs in the 
PRS until doing so added more noise than signal (threshold options: P ≤ 1, 5E-1, 2E-1, 1E-1, 
5E-2, 1E-2, 1E-3, 1E-4, 1E-6, and 5E-8). We identified the optimal p-value threshold as that 
which explained the most phenotypic variation for each trait. For the ASD PRS, we found 
that the threshold of P ≤ 0.1 explained the most case-pseudocontrol variance in SSC (as the 
SSC does not have independent control data, we generated pseudocontrol genotypes from 
the untransmitted parental alleles)20, 24. For the SCZ and EA PRS, we used the threshold 
identified by analyses accompanying the discovery GWAS as explaining the most 
variance12, 19. In the PGC’s 2014 schizophrenia analyses, a p-value threshold of P ≤ 0.05 
most commonly explained the most SCZ case-control variance in 40 leave-one-out 
analyses19. For educational attainment, constructing a PRS using a threshold of P ≤ 1 
explained the most variance in number years of education achieved in an independent 
sample12. For BMI, constructing a PRS using a threshold of P ≤ 0.2 explained the most 
variance in phenotypic body mass index among cases in the Simons Simplex Collection 
(Supplementary Note 5). These thresholds create the strongest polygenic risk scores for 
ASD, EA, SCZ and BMI, leaving us maximally powered to investigate the relationship 
between these four traits and ASDs.
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Next, we excluded SNPs that were poorly imputed in either SSC or PGC ASD (info score < 
0.6 in either cohort). The exception to this filtering rule was in SSC-specific analyses, (e.g., 
analysis of de novo variation) where our info threshold of 0.6 was the minimum in the SSC 
imputation only. For each trait, the polygenic risk scores for individuals in SSC and PGC 
ASD were then calculated as the product of the GWAS effect size (log odds or beta) at that 
SNP by the individual’s count of reference alleles at that SNP (0, 1 or 2), summed across all 
remaining markers. We implemented this scoring protocol using the score function in 
Plink31. If an individual was missing genetic data at a SNP in the summary statistics file, 
Plink calculated the expected score based on the cohort-wide allele frequency.
pTDT
We define pTDT deviation as:
where PRSC is the polygenic risk score for the child (proband or unaffected sibling). PRSMP 
is the mid-parent polygenic risk score:
SD(PRSMP) is the standard deviation of the sample-specific mid-parent PRS. For example, 
in SSC analysis, the SD(PRSMP) was the standard deviation of the mid-parent PRS 
distribution in SSC parents. We chose to standardize the pTDT deviation to improve 
interpretability and to facilitate comparison between different PRS. We standardized by 
PRSMP instead of PRSC because we expect the parent PRS distribution to be a better proxy 
for the population PRS distribution. The approach can be adapted to PRS from unaffected 
siblings, but using mid-parent PRS improves statistical power (Supplementary Note 6, 
Supplementary Table 20).
To evaluate whether the pTDT deviation is significantly different than 0, we defined the 
pTDT test statistic (tpTDT) as:
where n is the number of families included in the pTDT. We evaluate tpTDT as a two-sided, 
one-sample t-test.
We performed pTDT using the ASD, EA, SCZ and BMI PRS described above in four 
groups: SSC probands (n = 2,584), SSC unaffected siblings (n = 2,091), PGC ASD probands 
(n = 3,870), and the combination of SSC and PGC ASD probands (n = 6,454). As described 
in the main text (Figure 1a), each of the ASD, EA, and SCZ PRS were significantly over 
transmitted from parents to probands, but not to unaffected siblings (P < 1E-06 for all parent 
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to proband comparisons in either SSC or PGC ASD; P < 1E-15 for all parent to proband 
comparisons in combined SSC and PGC ASD; P > 0.05 for all unaffected sibling 
comparisons). In contrast, BMI PRS was not over transmitted to probands (P > 0.05 in both 
the SSC and PGC ASD). In a complementary permutation test, we randomly assigned case/
control labels to the affected and unaffected children in SSC. We then counted the number of 
times that the simulated difference in ASD PRS between affected and unaffected SSC 
children exceeded the observed difference (86 of 1,000,000 permutations = 0.0086%), 
consistent with the primary results (those in Figure 1a).
In our primary associations (Figure 1a, Supplementary Table 8), there were no statistically 
significant pTDT differences between the SSC and PGC ASD cohorts (Supplementary Table 
10). We accordingly combined SSC and PGC ASD for the analyses stratified by sex and IQ 
to increase statistical power (Figures 1b, 1c). In SSC, full scale IQ (FSIQ; SSC variable: 
sscfsiq) was derived from a number of scales and available for almost all probands (99.8%). 
Those scales included but were not limited to the Differential Ability Scales, Second 
Edition32; Mullen Scales of Early Learning33; and Wechsler battery34. Our full scale SSC IQ 
estimates were taken from the SSC’s ‘full scale deviation IQ’ variable when it was available, 
and ‘full scale ratio IQ’ when it was not35. FSIQ was measured heterogeneously across the 
contributing PGC ASD cohorts (Supplementary Table 2). To accommodate measurement 
differences, FSIQ was converted to broad groups for PGC consortium-level analyses (for the 
most part, numeric IQ values from PGC ASD were not available for this analysis). PGC 
ASD probands were assigned FSIQ levels 1-4 as follows: (1) FSIQ < 35; (2) 35 ≤ FSIQ < 
70; (3) 70 ≤ FSIQ < 90; (4) 90 ≤ FSIQ. In PGC ASD, 38.9% of probands had estimated IQ 
available. We divided each of SSC and PGC ASD by presence/absence of intellectual 
disability (ID) in the proband so that they could be analyzed together (SSC ID: IQ < 70; 
PGC ASD ID: IQ = 1 or IQ = 2). We repeated the IQ stratified analyses in SSC and PGC 
ASD separately, which further suggested no differences between the cohorts, despite the 
limited FSIQ data available in PGC ASD (Supplementary Tables 11, 12).
De novo variant analyses
We defined a group of de novo mutations strongly associated with ASD risk (Supplementary 
Table 14). We performed this analysis exclusively in SSC; we could not perform the analysis 
in PGC ASD because only common variant (GWAS) data was available. Our previous work 
has identified a subclass of de novo protein truncating variants (PTVs: frameshift variants, 
splice acceptor variants, splice donor variants, nonsense variants) that are a primary source 
of association to ASD21. De novo PTVs in this class are a) absent from the Exome 
Aggregation Consortium database, a reference sample of over 60,000 exomes, and b) found 
within a gene predicted to be intolerant of heterozygous loss of function variation 
(probability of loss of function intolerance (pLI) ≥ 0.9)22. In the SSC, de novo PTVs in this 
class were found in 7.1% of cases and 2.1% of unaffected siblings (P = 4.12E-14). PTVs 
outside of this contributing class are unassociated with ASD risk (observed in 7.8% of cases 
and 6.9% of unaffected siblings, P = 0.50) and are not associated with proband IQ (P = 0.76) 
(Supplementary Figure 8).
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As detailed in the main text, de novo copy number variants (CNVs) that delete a gene should 
have the same molecular impact as a PTV in that same gene. Contributing CNV deletions 
were seen in 2.5% of SSC cases and 0.5% of SSC unaffected siblings (P = 1.80E-08). All 
other types of de novo deletions were observed in 1.7% of cases and 1.4% of unaffected 
siblings, and were not associated with ASD risk (P = 0.48; Supplementary Figure 5). The 
associations between CNV categories and ASD risk are presented in the supplement and did 
not differ substantially when controlling for parental age at birth of child (Supplementary 
Table 21). Contributing deletions outside of our defined class were not associated with 
proband IQ (P = 0.34, Supplementary Figure 9). In contrast, de novo duplications of 
constrained genes are not disproportionately associated with ASD risk (P = 0.49; 
Supplementary Note 7; Supplementary Figure 10).
We identified a subset of de novo CNV deletions, primarily those containing loss of function 
intolerant genes, that account for most of the category’s association to ASDs (contributing 
CNV deletions; Supplementary Figure 4). Together, contributing PTVs and contributing 
CNV deletions formed a strong acting de novo variant category in SSC, known from here as 
contributing de novo variants (CDNVs). Multiple lines of evidence suggest CDNVs are 
robustly associated with ASD risk. CDNVs were seen in 9.4% of SSC cases (n = 221 of 
2,346) that were both sequenced and genotyped and 2.6% of SSC unaffected siblings (n = 45 
of 1,736) that were both sequenced and genotyped (P = 6.56E-20). CDNVs were very 
strongly associated with proband IQ (P = 5.80E-06; controlling for proband sex), while all 
other de novo PTVs and deletions (those not in the CDNV category) were not associated 
with proband IQ (P = 0.44, controlling for proband sex; Supplementary Figure 11).
As de novo variants are on average more severe when observed in ASD cases than in 
controls23, we could not estimate the amount of ASD risk conferred by CDNVs directly 
from the case-unaffected sibling odds ratio. As noted in the main text, we used the 
male:female CDNV carrier ratio to re-estimate the effect size for the event class, as 
described in De Rubeis et al., 2014. In brief, the approximately 4:1 male:female ratio among 
ASD cases suggests a different ASD liability threshold for males and females in the 
population. Regardless of whether that difference reflects etiology or ascertainment, it 
results in a direct mathematical relationship between the expected effect size of an event 
class and the male:female carrier ratio of cases. In the case of CDNVs, a variant class 
observed twice as frequently in female probands than in male probands (17.4% v 8.5%; P = 
5.26E-06; Supplementary Figure 12), we estimate an OR of approximately 203. This 
estimate exceeds that directly suggested by the CDNV case-control excess of 3.63.
We next examined the rate of CDNVs in SSC probands based on the number of adverse 
proband co-occurring neurological and developmental outcomes (Figure 2a). Previous 
studies have demonstrated that de novo PTVs and de novo CNVs are both associated with 
intellectual disability (IQ < 70) in ASD probands and positively associated with history of 
seizures1, 15. Motor delays are an additional neurodevelopmental co-morbitidy associated 
with autism spectrum disorder36. Here, we defined motor delay for SSC probands as 
walking unaided at or after 19 months, the age by which the great majority of children have 
begun to walk37. As hypothesized, motor delay, seizures, and low IQ were independently 
associated with CDNV rate in SSC probands after controlling for proband sex 
Weiner et al. Page 13
Nat Genet. Author manuscript; available in PMC 2017 November 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(Supplementary Table 15). CDNV rate was positively associated with the number of these 
adverse outcomes experienced by probands (Figure 2a, Supplementary Table 16). The 
decreasing male:female ratio among CDNV carriers as count of co-occurring 
neurodevelopmental outcomes increases suggests that with increased count of 
neurodevelopmental comorbidities comes, on average, increasingly severe de novo events 
(Supplementary Note 8, Supplementary Table 16). Multiple lines of evidence, including 
associations with IQ, male:female carrier ratio, and adverse co-occurring 
neurodevelopmental outcomes, suggest that CDNVs are strongly associated with ASD risk.
Using pTDT, we evaluated polygenic transmission in probands carrying at least one CDNV 
(Figure 2b, Supplementary Table 13). As this CDNV analysis is specific to SSC, the 
polygenic risk scores generated for the CDNV analysis used info score cutoffs from SSC 
imputation in order to increase the number of well-imputed SNPs retained for PRS. We 
restricted our analysis to those families with genotyped parents and probands with both 
genotype and exome sequence data (n = 2,346; n = 221 with CDNV). The cohort of 
probands with a CDNV is too small to determine whether the difference in transmission 
between probands that do and do not carry a CDNV is statistically significant. We also 
analyzed whether polygenic over transmission was seen in a more broadly defined set of de 
novo events (Supplementary Note 9, Supplementary Table 13).
Genetic heterogeneity and proband phenotype
We analyzed whether polygenic risk for ASD, EA and SCZ were each independently over 
transmitted to ASD cases. For each of SSC (n = 2,584 trios), PGC ASD (n = 3,870 trios) and 
SSC & PGC ASD combined (n = 6,454 trios), we performed a single logistic regression 
predicting proband/mid-parent status from polygenic risk for 1) ASD, 2) EA and 3) SCZ. 
We confirmed that the over transmission acts independently in each PRS (P < 2E-04 for all 
PRS in SSC + PGC ASD cohort; Supplementary Table 18).
To calculate the relationship between proband polygenic risk and ASD IQ (Figure 3c), we 
performed three separate linear regressions predicting full-scale proband IQ from the three 
PRS. The three ASD IQ - PRS associations are from three linear regressions predicting full-
scale proband IQ from the residualized and z-normed PRS. The other two PRS, CDNV 
presence/absence, proband sex, and the first 10 principal components of proband ancestry 
were regressed out of each PRS before analysis. These associations were performed in 
European ancestry Simons Simplex Collection probands (n = 1,674). The results were 
consistent with previously published association between the three polygenic risk scores and 
IQ in the general population (Supplementary Table 19)14. This relationship between 
polygenic risk and proband IQ holds when using mid-parent PRS and controlling for 
proband CDNV status (Supplementary Note 10, Supplementary Table 22).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
ASD probands over inherit polygenic risk for ASD, schizophrenia, and greater educational 
attainment. Transmission disequilibrium is shown in terms of standard deviations on the 
mid-parent distribution ± 1.96 standard error (95% confidence intervals). P-values denote 
the probability that the mean of the pTDT deviation distribution is 0 (two-sided, one-sample 
t-test). (a) ASD probands over inherit ASD associated polygenic risk in the Simon Simplex 
Collection (SSC, n = 2,584), Psychiatric Genomics Consortium Autism Group (PGC ASD, n 
= 3,870), and combined cohorts (n = 6,454). Unaffected siblings in SSC (n = 2,091) do not 
over inherit ASD associated polygenic risk. (b) Both male (n = 5,490) and female (n = 962) 
probands over inherit ASD associated polygenic risk in the SSC+PGC ASD combined 
cohort. (c) ASD probands with (n = 1,341) and without (n = 2,743) intellectual disability 
(full-scale IQ < 70) over inherit ASD associated polygenic risk in the SSC+PGC ASD 
combined cohort.
Weiner et al. Page 26
Nat Genet. Author manuscript; available in PMC 2017 November 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Contributing de novo mutations are associated with adverse neurological and developmental 
outcomes and act additively with polygenic burden to influence ASD risk. (a) Simons 
Simplex Collection (SSC) probands are grouped by their count of the following: delayed 
walking (≥ 19 months); presence of seizures; intellectual disability (full-scale IQ < 70) (n = 
1,476 with no outcomes; n = 719 with 1 outcome; n = 134 with 2 outcomes; n = 16 with 3 
outcomes). Contributing de novo variant (CDNV) rate is calculated by dividing the count of 
CDNVs by the count of individuals. The odds ratio (OR) was calculated via Poisson 
regression predicting CDNV count from case/control status for all controls (n = 1,736) and 
cases in the outcome category, controlling for maternal and paternal age at birth of the child. 
P-values above each diamond are from the Poisson regression and indicate the probability 
that the CDNV rate in cases is not different from the CDNV rate in controls. P-values 
between the diamonds are calculated from Poisson exact test and indicate the probability 
that there is no difference in CDNV rate between the two noted groups. Error bars are ± 1 
standard error. (b) pTDT analysis for SSC CDNV proband carriers (n = 221). Transmission 
disequilibrium is shown in terms of standard deviations on mid-parent distribution ± 1.96 
standard error (95% confidence intervals). P-values denote the probability that the mean of 
the pTDT deviation distribution is 0 (two-sided, one-sample t-test).
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Figure 3. 
(a) Additivity among orthogonal risk factors can yield high cumulative risk. (b) Polygenic 
risk scores (PRS) for ASDs, schizophrenia (SCZ), and educational attainment (EA) are not 
strongly associated at either the mid-parent level (above diagonal) or the pTDT deviation 
level (below diagonal). The table contains Pearson correlation coefficients and associated p-
values indicating the probability with which the true correlation is 0. Mid-parent correlations 
are controlled for first 10 principal components of parental ancestry. PRS are from European 
ancestry SSC families (n = 1,851). (c) Polygenic risk factors for ASD exhibit independent, 
distinct effects on IQ in European ancestry SSC probands (n = 1,674). P-values, which 
estimate the probability of no association between each PRS and IQ, are calculated from 
linear regression. We predicted full-scale IQ from each PRS, z-normalized following 
residualization for the other two PRS, CDNV presence/absence, proband sex, and the first 
10 principal components of proband ancestry. Each panel displays the linear association 
between full-scale proband IQ and the normalized PRS.
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